EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Guardant Health's enterprise value is $6,069.8 Mil.
Guardant Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $739.0 Mil. Therefore, Guardant Health's EV-to-Revenue for today is 8.21.
The historical rank and industry rank for Guardant Health's EV-to-Revenue or its related term are showing as below:
GH'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.6 Med: 21.91 Max: 88.62
Current: 8.21
During the past 9 years, the highest EV-to-Revenue of Guardant Health was 88.62. The lowest was 3.60. And the median was 21.91.
GH's EV-to-Revenue is ranked worse than 83.64% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.48
vs GH: 8.21
As of today (2025-04-16), Guardant Health's stock price is $44.85.
Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $6.02. Therefore, Guardant Health's PS Ratio for today is 7.45.
Guardant Health EV-to-Revenue Historical Data
The historical data trend for Guardant Health's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Guardant Health's EV-to-Revenue
For the Diagnostics & Research subindustry, Guardant Health's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Guardant Health's EV-to-Revenue falls into.
Guardant Health's current Enterprise Value is $6,069.8 Mil.
Guardant Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $739.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) EV-to-Revenue Explanation
Guardant Health's share price for today is $44.85.
Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Guardant Health's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 